Bausch + Lomb Corporation (BLCO)
NYSE: BLCO · Real-Time Price · USD
18.49
-0.11 (-0.59%)
Feb 26, 2026, 4:00 PM EST - Market closed
Bausch + Lomb Revenue
In the year 2025, Bausch + Lomb had annual revenue of $5.10B with 6.47% growth. Bausch + Lomb had revenue of $2.45B in the quarter ending December 31, 2025, with 91.14% growth.
Revenue (ttm)
$5.78B
Revenue Growth
+29.08%
P/S Ratio
1.28
Revenue / Employee
$392,385
Employees
13,000
Market Cap
6.55B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.10B | 310.00M | 6.47% |
| Dec 31, 2024 | 4.79B | 645.00M | 15.56% |
| Dec 31, 2023 | 4.15B | 378.00M | 10.03% |
| Dec 31, 2022 | 3.77B | 3.00M | 0.08% |
| Dec 31, 2021 | 3.77B | 353.00M | 10.35% |
| Dec 31, 2020 | 3.41B | -366.00M | -9.69% |
| Dec 31, 2019 | 3.78B | 113.00M | 3.08% |
| Dec 31, 2018 | 3.67B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Baxter International | 11.24B |
| Solventum | 8.40B |
| Avantor | 6.55B |
| Align Technology | 4.03B |
| AptarGroup | 3.78B |
| Teleflex | 3.19B |
| Envista Holdings | 2.72B |
| ICU Medical | 2.23B |
BLCO News
- 2 days ago - Ophthalmology and Therapy Publishes Findings Showing Lifestyle-Driven Rise in Ocular Redness and Differentiated Role of LUMIFY® - Business Wire
- 8 days ago - Bausch + Lomb Corporation (BLCO) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 8 days ago - Bausch + Lomb Announces Fourth-Quarter and Full-Year 2025 Results, Provides 2026 Guidance - Business Wire
- 5 weeks ago - Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18 - Business Wire
- 6 weeks ago - Bausch + Lomb Corporation (BLCO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 7 weeks ago - Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S. - Business Wire
- 7 weeks ago - Bausch + Lomb Completes Refinancing of Outstanding Term B Loans - Business Wire
- 2 months ago - Bausch + Lomb to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Business Wire